Larimar Therapeutics IncNASDAQ:LRMR
- LAST PRICE6.3500
- TODAY'S CHANGE (%)-0.3400 (-5.0822%)
- Bid / Lots6.3300/ 6
- Ask / Lots6.3700/ 6
- Open / Previous Close6.5300 / 6.6900
- Day Range
- 52 Week Range
- Volume513,882
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LRMR |
|---|---|---|
| 09:32 ET | 6434 | 6.5814 |
| 09:33 ET | 2500 | 6.5713 |
| 09:37 ET | 3492 | 6.43 |
| 09:39 ET | 5955 | 6.35 |
| 09:42 ET | 7625 | 6.3243 |
| 09:44 ET | 4969 | 6.36 |
| 09:46 ET | 915 | 6.39 |
| 09:48 ET | 200 | 6.39 |
| 09:50 ET | 14894 | 6.3258 |
| 09:51 ET | 478 | 6.32 |
| 09:53 ET | 8529 | 6.27 |
| 09:55 ET | 4401 | 6.19 |
| 09:57 ET | 7902 | 6.27 |
| 10:00 ET | 4726 | 6.22 |
| 10:02 ET | 1299 | 6.2 |
| 10:04 ET | 3697 | 6.17 |
| 10:06 ET | 2425 | 6.16 |
| 10:08 ET | 9943 | 6.146 |
| 10:09 ET | 9111 | 6.1963 |
| 10:11 ET | 1548 | 6.17 |
| 10:13 ET | 6510 | 6.15 |
| 10:15 ET | 410 | 6.1201 |
| 10:18 ET | 2297 | 6.17 |
| 10:20 ET | 2175 | 6.12 |
| 10:22 ET | 7427 | 6.165 |
| 10:24 ET | 1780 | 6.27 |
| 10:26 ET | 6603 | 6.25 |
| 10:27 ET | 2258 | 6.34 |
| 10:29 ET | 21313 | 6.37 |
| 10:31 ET | 4396 | 6.34 |
| 10:33 ET | 761 | 6.365 |
| 10:36 ET | 4170 | 6.35 |
| 10:38 ET | 4294 | 6.3409 |
| 10:40 ET | 6772 | 6.315 |
| 10:42 ET | 10538 | 6.33 |
| 10:44 ET | 1800 | 6.35 |
| 10:45 ET | 9789 | 6.35 |
| 10:47 ET | 2695 | 6.34 |
| 10:49 ET | 7275 | 6.3201 |
| 10:51 ET | 5705 | 6.275 |
| 10:54 ET | 4010 | 6.28 |
| 10:56 ET | 128 | 6.2682 |
| 10:58 ET | 1600 | 6.26 |
| 11:00 ET | 5601 | 6.27 |
| 11:02 ET | 3561 | 6.32 |
| 11:03 ET | 685 | 6.306 |
| 11:05 ET | 900 | 6.31 |
| 11:07 ET | 1565 | 6.29 |
| 11:09 ET | 500 | 6.27 |
| 11:12 ET | 5950 | 6.29 |
| 11:14 ET | 1637 | 6.3 |
| 11:16 ET | 4951 | 6.33 |
| 11:18 ET | 906 | 6.32 |
| 11:20 ET | 1355 | 6.3 |
| 11:21 ET | 5800 | 6.28 |
| 11:23 ET | 3225 | 6.26 |
| 11:25 ET | 3799 | 6.2518 |
| 11:27 ET | 10227 | 6.29 |
| 11:30 ET | 3300 | 6.3 |
| 11:32 ET | 3506 | 6.3 |
| 11:34 ET | 1962 | 6.31 |
| 11:36 ET | 1095 | 6.3 |
| 11:38 ET | 200 | 6.3 |
| 11:39 ET | 600 | 6.3 |
| 11:41 ET | 622 | 6.3 |
| 11:43 ET | 1400 | 6.3 |
| 11:45 ET | 2600 | 6.3 |
| 11:48 ET | 8377 | 6.3 |
| 11:50 ET | 13980 | 6.2 |
| 11:52 ET | 10785 | 6.16 |
| 11:54 ET | 1000 | 6.176 |
| 11:56 ET | 677 | 6.15 |
| 11:57 ET | 2350 | 6.21 |
| 11:59 ET | 6140 | 6.28 |
| 12:01 ET | 8176 | 6.3 |
| 12:03 ET | 869 | 6.2956 |
| 12:06 ET | 600 | 6.31 |
| 12:08 ET | 1600 | 6.31 |
| 12:10 ET | 28637 | 6.31 |
| 12:12 ET | 720 | 6.31 |
| 12:14 ET | 700 | 6.2901 |
| 12:15 ET | 200 | 6.33 |
| 12:17 ET | 2760 | 6.3 |
| 12:19 ET | 1300 | 6.31 |
| 12:21 ET | 640 | 6.31 |
| 12:24 ET | 300 | 6.3 |
| 12:26 ET | 1245 | 6.29 |
| 12:28 ET | 600 | 6.29 |
| 12:30 ET | 500 | 6.29 |
| 12:32 ET | 5758 | 6.3001 |
| 12:33 ET | 119 | 6.315 |
| 12:35 ET | 450 | 6.33 |
| 12:37 ET | 100 | 6.315 |
| 12:39 ET | 1600 | 6.33 |
| 12:42 ET | 300 | 6.365 |
| 12:44 ET | 11726 | 6.45 |
| 12:46 ET | 451 | 6.38 |
| 12:48 ET | 300 | 6.375 |
| 12:50 ET | 800 | 6.35 |
| 12:51 ET | 498 | 6.345 |
| 12:53 ET | 925 | 6.38 |
| 12:55 ET | 825 | 6.37 |
| 12:57 ET | 1420 | 6.37 |
| 01:00 ET | 1600 | 6.41 |
| 01:02 ET | 1200 | 6.39 |
| 01:04 ET | 845 | 6.35 |
| 01:06 ET | 920 | 6.36 |
| 01:08 ET | 453 | 6.35 |
| 01:09 ET | 1718 | 6.32 |
| 01:11 ET | 800 | 6.32 |
| 01:13 ET | 1700 | 6.3 |
| 01:15 ET | 1124 | 6.305 |
| 01:18 ET | 1000 | 6.3 |
| 01:20 ET | 400 | 6.31 |
| 01:22 ET | 500 | 6.315 |
| 01:24 ET | 2692 | 6.34 |
| 01:26 ET | 504 | 6.36 |
| 01:27 ET | 484 | 6.33 |
| 01:29 ET | 3067 | 6.34 |
| 01:31 ET | 2100 | 6.315 |
| 01:33 ET | 2087 | 6.35 |
| 01:36 ET | 8758 | 6.35 |
Today
DJ Larimar Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co., from 56 minutes ago by Dow Jones
56 minutes ago by Dow JonesLarimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024, from 6 hours ago by Dow Jones
6 hours ago by Dow Jones
Oct 31, 2024
DJ Larimar Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co., from 5:51AM ET on Thursday Oct 31, 2024 by Dow Jones
5:51AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 30, 2024
*DJ Larimar Therapeutics 3Q Loss/Shr 24c >LRMR, from 7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
7:00AM ET on Wednesday Oct 30, 2024 by Dow JonesLarimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results, from 7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Larimar Therapeutics Inc | 426.9M | -5.5x | --- |
Korro Bio Inc | 442.3M | -2.9x | --- |
Neurogene Inc | 448.5M | -4.2x | --- |
Prime Medicine Inc | 401.5M | -1.6x | --- |
Q32 Bio Inc | 401.4M | -4.3x | --- |
Omeros Corp | 391.1M | -1.9x | --- |
Company Information
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Contact Information
- Headquarters
- THREE BALA PLAZA EAST. SUITE 506BALA CYNWYD, PA, United States 19004
- Phone
- 617-622-4003
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joseph Truitt
- President, Chief Executive Officer, Director
- Carole Ben-Maimon
- Chief Financial Officer, Secretary
- Michael Celano
- Chief Medical Officer
- Russell Clayton
- Chief Development Officer
- Gopi Shankar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $426.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 63.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.92 |
EPS | $-1.15 |
Book Value | $1.86 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
